1. Home
  2. AKBA vs CBAN Comparison

AKBA vs CBAN Comparison

Compare AKBA & CBAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • CBAN
  • Stock Information
  • Founded
  • AKBA 2007
  • CBAN 1975
  • Country
  • AKBA United States
  • CBAN United States
  • Employees
  • AKBA N/A
  • CBAN N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • CBAN Major Banks
  • Sector
  • AKBA Health Care
  • CBAN Finance
  • Exchange
  • AKBA Nasdaq
  • CBAN Nasdaq
  • Market Cap
  • AKBA 336.2M
  • CBAN 285.4M
  • IPO Year
  • AKBA 2014
  • CBAN 1998
  • Fundamental
  • Price
  • AKBA $1.93
  • CBAN $16.29
  • Analyst Decision
  • AKBA Strong Buy
  • CBAN
  • Analyst Count
  • AKBA 3
  • CBAN 0
  • Target Price
  • AKBA $6.50
  • CBAN N/A
  • AVG Volume (30 Days)
  • AKBA 6.1M
  • CBAN 86.5K
  • Earning Date
  • AKBA 05-08-2025
  • CBAN 04-23-2025
  • Dividend Yield
  • AKBA N/A
  • CBAN 2.82%
  • EPS Growth
  • AKBA N/A
  • CBAN 9.88
  • EPS
  • AKBA N/A
  • CBAN 1.36
  • Revenue
  • AKBA $160,180,000.00
  • CBAN $112,401,000.00
  • Revenue This Year
  • AKBA $23.40
  • CBAN $14.25
  • Revenue Next Year
  • AKBA $58.44
  • CBAN $6.28
  • P/E Ratio
  • AKBA N/A
  • CBAN $12.02
  • Revenue Growth
  • AKBA N/A
  • CBAN 1.93
  • 52 Week Low
  • AKBA $0.80
  • CBAN $10.33
  • 52 Week High
  • AKBA $2.89
  • CBAN $18.49
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 46.74
  • CBAN 47.76
  • Support Level
  • AKBA $1.83
  • CBAN $15.94
  • Resistance Level
  • AKBA $1.99
  • CBAN $16.61
  • Average True Range (ATR)
  • AKBA 0.19
  • CBAN 0.35
  • MACD
  • AKBA -0.03
  • CBAN 0.01
  • Stochastic Oscillator
  • AKBA 15.42
  • CBAN 37.89

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About CBAN Colony Bankcorp Inc.

Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.

Share on Social Networks: